CMND
NASDAQClearmind Medicine Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.98-6.82 (-77.50%)
2026-04-142026-07-17
News · 26 weeks104-29%
2026-01-252026-07-19
Mix5690d
- SEC Filings27(48%)
- Other24(43%)
- Insider5(9%)
Latest news
25 items- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and AddictionVancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: "At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secreta
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAIVancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane). Leveraging a nasal drug‑delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution. Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human TrialPrincipal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, "Inside MEAI," during which the Company’s CEO and the leading investigators of the Company’s ongoing first-in-human clinical trial of C
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery InitiativeVancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental health problems, with a focus on Alcohol Use Disorder and other addiction related diagnoses, today announced that it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) about MEAI’s potential as an innovative, empirically-evidenced intervention for the treatment of addiction. Clearmind proposes an innovative model to enable inexpensive, scalable, and clinically effective
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAIVancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, such as addictions and weight-loss, announced continued progress in evaluating intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane) as a potential additional route of administration, initially for the treatment of alcohol use disorder (AUD). The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studi
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent StrengthVancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has been egranted an additional U.S. Patent, No. 12,357,590, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO). This latest patent builds directly on the Company’s previously issued U.S. Patent No. 12,350,242 and further strengthens its intellectual property protection around the MEAI (5-methoxy-2-am
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II TrialVancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, a
- SECSEC Form EFFECT filed by Clearmind Medicine Inc.EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
- INSIDERLarge owner Hrt Financial Lp sold $73,192 worth of Class A Shares (22,139 units at $3.31), decreasing direct ownership by 21% to 81,353 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Granted U.S. Patent for Binge Behavior RegulatorsVancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO). The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, inc
- INSIDERLarge owner Hrt Financial Lp sold $10,568 worth of shares (3,183 units at $3.32), decreasing direct ownership by 3% to 103,492 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- INSIDERLarge owner Hrt Financial Lp sold $7,063 worth of shares (2,102 units at $3.36), decreasing direct ownership by 2% to 106,675 units (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- PRClearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical TrialVancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All healthy participants in the first stage of the trial have been treated with escalating dose levels of the Company's proprietary drug candidate,
- SECSEC Form POS AM filed by Clearmind Medicine Inc.POS AM - Clearmind Medicine Inc. (0001892500) (Filer)
- SECSEC Form 6-K filed by Clearmind Medicine Inc.6-K - Clearmind Medicine Inc. (0001892500) (Filer)
- INSIDERLarge owner Hrt Financial Lp bought $330,335 worth of shares (2,159,052 units at $0.15) and sold $27,698 worth of shares (225,191 units at $0.12) (SEC Form 4)4 - Clearmind Medicine Inc. (0001892500) (Issuer)
CMND FAQ
4 questionsWhere does CMND stock trade?
Clearmind Medicine Inc. (CMND) is listed on NASDAQ.What sector and industry is CMND in?
Clearmind Medicine Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to CMND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CMND side-by-side with any of them on Quantisnow.How can I track CMND on Quantisnow?
Quantisnow aggregates Clearmind Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMND to receive live email and push alerts on every new disclosure.